Filing Flows › Relay Therapeutics (RLAY) › R&D spending
Relay Therapeutics (RLAY) R&D spending by quarter
Relay Therapeutics' R&D spending was $76.5M in Q2 2026 (second quarter 2026), +8% from Q1 2026. Over the last 5 quarters it ranged from $55.4M (Q4 2025) to $76.5M (Q2 2026).
| Quarter | R&D spending | Q/Q | Y/Y |
|---|---|---|---|
| Q2 2026 | $76.5M | +8% | +20% |
| Q1 2026 | $70.6M | +27% | -4% |
| Q4 2025 | $55.4M | -13% | — |
| Q2 2025 | $63.9M | -13% | — |
| Q1 2025 | $73.8M | — | — |
Q2 2026 at a glance
Relay Therapeutics, Q2 2026: revenue $350K (-48% year over year), net loss $83.7M, operating cash flow −$54.1M. The chart follows the revenue to costs, profit and cash.
Questions
What is Relay Therapeutics' R&D spending?
Relay Therapeutics' R&D spending was $76.5M in Q2 2026 (second quarter 2026), +8% from Q1 2026.
How has Relay Therapeutics' R&D spending changed?
Over the last 5 quarters it ranged from $55.4M (Q4 2025) to $76.5M (Q2 2026).